 |
|
Cost-effectiveness of Postexposure Prophylaxis After Sexual or Injection-Drug Exposure to Human Immunodeficiency Virus
Steven D. Pinkerton, PhD;
Jeffrey N. Martin, MD, MPH;
Michelle E. Roland, MD;
Mitchell H. Katz, MD;
Thomas J. Coates, PhD;
James O. Kahn, MD
Arch Intern Med. 2004;164:46-54.
Background The cost-effectiveness of interventions that provide human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) to individuals after sexual or injection-drug use exposures depends on the distribution of exposure routes, prevalence of infection among source partners, adherence to PEP regimens, medical care costs, and prevailing epidemiologic contexts, among other factors.
Objective To determine the cost-effectiveness of a comprehensive program to prevent HIV infection after sexual or injection-drug use exposure for 401 persons seeking PEP in an urban community.
Methods We conducted a retrospective cost analysis to evaluate the cost of the PEP intervention, then combined this information with model-based effectiveness estimates to determine the PEP program's "cost-utility ratio," which is the ratio of net program costs to the total number of quality-adjusted life-years (QALYs) saved by the program.
Results The average cost of the PEP regimen was $1222, and the total cost of the program was $450 970. The PEP program prevented an estimated 1.26 HIV infections, saved 11.74 QALYs, and averted $281 323 in future HIV-related medical care costs. The overall cost-utility ratio was $14 449 per QALY saved. When analysis was restricted to men reporting receptive anal intercourse, the savings in averted HIV-related medical care costs exceeded the cost of the program. The results were generally robust to changes in key parameter values but were sensitive to assumptions about the HIV transmission probability for receptive anal intercourse.
Conclusions For this study population, HIV PEP was cost-effective by conventional standards and cost-saving for persons seeking PEP after male-male receptive anal intercourse.
From the Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee (Dr Pinkerton); the University of California– San Francisco Positive Health Program at San Francisco General Hospital (Drs Martin, Roland, Katz, and Kahn); the Center for AIDS Prevention Studies, University of California–San Francisco (Drs Martin and Coates); and the San Francisco Department of Public Health (Dr Katz). Dr Roland has received honorarium from GlaxoSmithKline, Bristol-Myers Squibb, and Agouron Pharmaceuticals.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
Hornberger et al.
Med Decis Making 2007;27:789-821.
ABSTRACT
Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1
Cohen et al.
ANN INTERN MED 2007;146:591-601.
ABSTRACT
| FULL TEXT
Is Nonoccupational Postexposure Prophylaxis Cost-Effective?
AIDS Clin Care 2004;2004:5-5.
FULL TEXT
|
